These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29705214)

  • 1. Preclinical characterization and clinical evaluation of tacrolimus eye drops.
    Luaces-Rodríguez A; Touriño-Peralba R; Alonso-Rodríguez I; García-Otero X; González-Barcia M; Rodríguez-Ares MT; Martínez-Pérez L; Aguiar P; Gómez-Lado N; Silva-Rodríguez J; Herranz M; Ruibal-Morell Á; Lamas MJ; Otero-Espinar FJ; Fernández-Ferreiro A
    Eur J Pharm Sci; 2018 Jul; 120():152-161. PubMed ID: 29705214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection.
    Li Q; Li Z; Zeng W; Ge S; Lu H; Wu C; Ge L; Liang D; Xu Y
    Eur J Pharm Sci; 2014 Oct; 62():115-23. PubMed ID: 24905830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of topically applied tacrolimus dissolved in Marinosolv, a novel aqueous eye drop formulation.
    Siegl C; König-Schuster M; Nakowitsch S; Koller C; Graf P; Unger-Manhart N; Schindlegger Y; Kirchoff N; Knecht C; Prieschl-Grassauer E; Sipos W
    Eur J Pharm Biopharm; 2019 Jan; 134():88-95. PubMed ID: 30465821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Galenic and analytic development of tacrolimus 0.06% eye drops].
    Gauthier AS; Rival B; Sahler J; Fagnoni-Legat C; Limat S; Guillaume Y; Delbosc B
    J Fr Ophtalmol; 2013 May; 36(5):408-13. PubMed ID: 23218600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the pharmacokinetics and ocular tolerance of a microemulsion containing tacrolimus.
    Silva-Cunha A; da Silva GR; de Castro WV; Fialho SL
    J Ocul Pharmacol Ther; 2014 Feb; 30(1):59-65. PubMed ID: 24199740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cyclosporine eye drops: A 4-year retrospective study (2009-2013)].
    Kauss Hornecker M; Charles Weber S; Brandely Piat ML; Darrodes M; Jomaa K; Chast F
    J Fr Ophtalmol; 2015 Oct; 38(8):700-8. PubMed ID: 26371985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron Emission Tomography for the Development and Characterization of Corneal Permanence of Ophthalmic Pharmaceutical Formulations.
    Fernández-Ferreiro A; Silva-Rodríguez J; Otero-Espinar FJ; González-Barcia M; Lamas MJ; Ruibal A; Luaces-Rodriguez A; Vieites-Prado A; Sobrino T; Herranz M; García-Varela L; Blanco-Mendez J; Gil-Martínez M; Pardo M; Moscoso A; Medín-Aguerre S; Pardo-Montero J; Aguiar P
    Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):772-780. PubMed ID: 28146242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Ocular Tolerance of Three Tacrolimus Topical Pharmaceutical Preparations by Bovine Corneal Opacity and Permeability Test.
    Pastor-Clerigues A; Serrano A; Milara J; Marti-Bonmati E; Lopez-Perez FJ; Garcia-Montanes S; Sanfeliu J; Saval-Victoria AC; Cortijo J
    Curr Eye Res; 2016 Jul; 41(7):890-6. PubMed ID: 26554729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis.
    Wan Q; Tang J; Han Y; Wang D; Ye H
    Ophthalmic Res; 2018; 59(3):126-134. PubMed ID: 28803239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis.
    Wakamatsu TH; Tanaka M; Satake Y; Dogru M; Fukagawa K; Igarashi A; Fujishima H
    Mol Vis; 2011 Apr; 17():932-8. PubMed ID: 21541276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability.
    Zeng W; Li Q; Wan T; Liu C; Pan W; Wu Z; Zhang G; Pan J; Qin M; Lin Y; Wu C; Xu Y
    Colloids Surf B Biointerfaces; 2016 May; 141():28-35. PubMed ID: 26820107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Tacrolimus for Chronic Allergic Conjunctival Disease with and without Atopic Dermatitis.
    Shoji J; Ohashi Y; Fukushima A; Miyazaki D; Uchio E; Takamura E; Fujishima H; Namba K; Kumagai N; Ebihara N; Okamoto S
    Curr Eye Res; 2019 Jul; 44(7):796-805. PubMed ID: 30947551
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement.
    Fukushima A; Ohashi Y; Ebihara N; Uchio E; Okamoto S; Kumagai N; Shoji J; Takamura E; Nakagawa Y; Namba K; Fujishima H; Miyazaki D
    Br J Ophthalmol; 2014 Aug; 98(8):1023-7. PubMed ID: 24695688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.
    Labcharoenwongs P; Jirapongsananuruk O; Visitsunthorn N; Kosrirukvongs P; Saengin P; Vichyanond P
    Asian Pac J Allergy Immunol; 2012 Sep; 30(3):177-84. PubMed ID: 23156846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Safety and Efficacy of Tacrolimus 0.1% in Severe Pediatric Vernal Keratoconjunctivitis.
    Caputo R; Marziali E; de Libero C; Di Grande L; Danti G; Virgili G; Villani E; Mori F; Bacci GM; Lucenteforte E; Pucci N
    Cornea; 2021 Nov; 40(11):1395-1401. PubMed ID: 34029239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cysteamine polysaccharide hydrogels: Study of extended ocular delivery and biopermanence time by PET imaging.
    Luaces-Rodríguez A; Díaz-Tomé V; González-Barcia M; Silva-Rodríguez J; Herranz M; Gil-Martínez M; Rodríguez-Ares MT; García-Mazás C; Blanco-Mendez J; Lamas MJ; Otero-Espinar FJ; Fernández-Ferreiro A
    Int J Pharm; 2017 Aug; 528(1-2):714-722. PubMed ID: 28634142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study.
    Magalhaes OA; Marinho DR; Kwitko S
    Br J Ophthalmol; 2013 Nov; 97(11):1395-8. PubMed ID: 24008822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study.
    Moscovici BK; Holzchuh R; Sakassegawa-Naves FE; Hoshino-Ruiz DR; Albers MB; Santo RM; Hida RY
    Cont Lens Anterior Eye; 2015 Oct; 38(5):373-8. PubMed ID: 25956572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical treatment of dry eye using 0.03% tacrolimus eye drops.
    Moscovici BK; Holzchuh R; Chiacchio BB; Santo RM; Shimazaki J; Hida RY
    Cornea; 2012 Aug; 31(8):945-9. PubMed ID: 22511024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus Eye Drops as Adjunct Therapy in Severe Corneal Endothelial Rejection Refractory to Corticosteroids.
    Ghaffari R; Ghassemi H; Zarei-Ghanavati M; Latifi G; Dehghani S; Haq Z; Djalilian AR
    Cornea; 2017 Oct; 36(10):1195-1199. PubMed ID: 28817391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.